Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss of $0.47/Share
August 9, 2016 7:28 AM EDTSyndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.47), versus ($440.52) reported last year. Revenue for the quarter came in at $305 thousand, versus $17 thousand reported last year.
For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.
... More